Hans Hammers, MD, PhD
Patients with metastatic renal cell carcinoma had an objective response rate (ORR) of 40% and a 2-year overall survival (OS) rate of nearly 70% with the immune checkpoint combination of ipilimumab (Yervoy) and nivolumab (Opdivo), in phase I results from CheckMate-016 now published online in the Journal of Clinical Oncology.
Of the 12 patients in the N3I1 group who experienced at least one ipilimumab dose delay, 3 (6.4%) were due to hematologic toxicity. Fourteen (29.8%) patients in the N1I3 arm had one or more ipilimumab dose delays, 2 (4.3%) caused by hematologic toxicity.
Hammers HJ, Plimack ER, Infante JR, et al. Safety and efficacy of nivolumab in combination with ipilimumab in metastatic renal cell carcinoma: the CheckMate 016 study [published online July 5, 2017]. J Clin Oncol. doi: 10.1200/JCO.2016.72.1985.
... to read the full story